The Stanford Cancer Center is applying to the National Cancer Institute (NCI) for five years of funding of a Cancer Center Support Grant (CCSG) and for designation as a Comprehensive Cancer Center. Over the past three years, the Cancer Center has grown from 260 to 311 members representing four Schools within Stanford University (Medicine, Engineering, Humanities and Sciences and Law) and the Northern California Cancer Center with which Stanford has had a long-standing, scientifically productive relationship under a formal affiliation agreement. The CCSG proposal is built upon institutional strengths in technology development, particularly in the fields of imaging, biotechnology, informatics, and chemical engineering. The integration of these research areas into the fields of cancer biology, immunology, genetics and stem cell biology in the development of new approaches to cancer prevention, diagnosis and treatment is the distinguishing feature of this Cancer Center. Ten programs cover the areas of basic, translational/clinical, and population science research in cancer (Cancer Biology, Radiation Biology, Cancer Stem Cells, Cancer Imaging and Early Detection, Molecular Therapeutics, Lymphoma and Hodgkin Disease, Cancer Immunology and Immunotherapy, Hematopoietic Cell Transplantation and Immune Reconstitution, Cancer Epidemiology, and Cancer Prevention and Control). Eleven Shared Resources support the basic and translational/clinical investigation that is carried out in the Center. Based on current NCI base funding of $36 million and with $58 million in other NIH support and $16 million in other peer-reviewed cancer-relevant funding, the Center is requesting $5.3 million in direct costs to support its activities. With the advent of two new buildings for basic and translational research, new recruitment, and increased collaborative interactions, the Center is poised to make significant contributions to cancer research in the new funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA124435-08S3
Application #
9022012
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
2007-06-04
Project End
2016-05-31
Budget Start
2015-06-01
Budget End
2016-05-31
Support Year
8
Fiscal Year
2015
Total Cost
$2,249,153
Indirect Cost
$819,599
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94304
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15
Champion, Magali; Brennan, Kevin; Croonenborghs, Tom et al. (2018) Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. EBioMedicine 27:156-166
Zhou, Mu; Leung, Ann; Echegaray, Sebastian et al. (2018) Non-Small Cell Lung Cancer Radiogenomics Map Identifies Relationships between Molecular and Imaging Phenotypes with Prognostic Implications. Radiology 286:307-315
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471

Showing the most recent 10 out of 322 publications